CGTX Cognition Therapeutics, Inc.
Healthcare$1.24-1.59%ClosedMarket Cap: $91.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.76
P/S
0.00
EV/EBITDA
-2.63
DCF Value
$0.60
FCF Yield
-21.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.7%
ROA
-54.2%
ROIC
-141.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-8.8M | $-4.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-13.7M | $-3.3M | $— | — |
| FY null | $0.00 | NaN% | $-47.8M | $-23.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-6.4M | $-4.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-14.0M | $-6.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-13.8M | $-8.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.7M | $-7.8M | $— | — |
| FY null | $0.00 | NaN% | $-54.0M | $-34.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.5M | $-9.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-14.7M | $-7.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-14.1M | $-9.2M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-15.2M | $-8.1M | $-0.26 | — |